685514-01-6

Basic information

• Product Name: 1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]-
• Synonyms: 1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]-;1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridin-5-ol;1-[Tris(1-methylethyl)silyl]-1H-pyrrolo[2,3-b]pyridin-5-ol;1-triisopropylsilylpyrrolo[2,3-b]pyridin-5-ol;1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-4-sulfonic acid
• CAS NO: 685514-01-6
• Molecular Formula: C₁₆H₂₆N₂OSi
• Molecular Weight: 290.48
• Mol File: 685514-01-6.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 341.6°C at 760 mmHg
• Flash Point: 160.4°C
• Appearance: /
• Density: 1.03g/cm³
• Vapor Pressure: 4.03E-05mmHg at 25°C
• Refractive Index: 1.534
• PKA: 8.50±0.40(Predicted)
• CAS DataBase Reference: 1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]-(685514-01-6)
• EPA Substance Registry System: 1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]-(685514-01-6)

Safety Data

• Hazardous Substances Data: 685514-01-6(Hazardous Substances Data)

Usage

General Description

1H-Pyrrolo[2,3-b]pyridin-5-ol, 1-[tris(1-methylethyl)silyl]- is a chemical compound that is noted for its complex and unique structure featuring a tris(1-methylethyl)silyl group. This type of compound falls under the category of pyrrolopyridines, which are a type of heterocyclic aromatic organic compounds. These compounds usually contain nitrogen atoms and are commonly utilized in pharmaceutical and medicinal chemistry due to their potential biological activities. However, detailed information about its specific properties, uses and safety measures is not widely available, suggesting that it is primarily of interest in advanced chemical research and experimentation.

InChI:InChI=1/C16H26N2OSi/c1-11(2)20(12(3)4,13(5)6)18-8-7-14-9-15(19)10-17-16(14)18/h7-13,19H,1-6H3

Upstream product

• 13154-24-0 triisopropylsilyl chloride 
• 183208-35-7 5-bromo-1H-pyrrolo[2,3-b]pyridine 
• 858116-66-2 5-bromo-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine 
• 685513-98-8 4-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-5-ol 
• 651744-48-8 4-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 
• 55052-28-3 4-chloro-7-azaindole 

Downstream Products

• 1235865-76-5 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4’-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1’-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid methyl ester 
• 1235865-77-6 [2-((1H-pyrrolo [2,3-b]pyridin-5-yl)oxy)-4-(4-((4’-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1’-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid] 
• 1257044-40-8 2-((1H-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-(4-((4'-chloro-5,5-dimethyl-3,4,5,6-tetrahydro-[1,1-biphenyl]-2-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)phenyl)sulfonyl)benzamide 

Relevant articles and documents

Novel BCL-2/BCL-XL inhibitor, pharmaceutical composition and application

The invention relates to a compound for inhibiting the activity of Bcl-2/BCL-XL anti-apoptotic protein, a composition containing the compound and application of the compound serving as a synthetic drug, in particular to application of the compound serving as a drug for synthesizing a Bcl-2/BCL-XL anti-apoptotic protein inhibitor and application of the compound to cancer.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES

Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds.